Watch out Sanofi: Takeda's new da­ta on dengue vac­cine is good news for PhI­II tri­al

Prospects for Take­da’s dengue vac­cine just turned brighter fol­low­ing fresh da­ta from the com­pa­ny’s Phase II tri­al. For Take­da, the da­ta is like­ly wel­come con­sid­er­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER